糖尿病和 CKD 患者的管理：来自“肾脏病：改善全球预后”（KDIGO）争议会议的结论。
Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
机构信息
George Institute for Global Health, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, New South Wales, Australia.
Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.
出版信息
Kidney Int. 2016 Dec;90(6):1175-1183. doi: 10.1016/j.kint.2016.09.010.
The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.
目前，全世界的糖尿病患病率已达到流行程度，预计到 2040 年将增至 6.42 亿人。在大多数发达国家，糖尿病已成为终末期肾病（ESKD）的主要病因，全世界 ESKD 患者人数的增长与糖尿病患者人数的增长是一致的。患有肾脏疾病的人发生心血管疾病和死亡的风险明显增加。目前正在开发几种针对患有糖尿病的慢性肾病患者的新疗法和新型研究药物。本次会议的目的是评估我们目前在最佳血糖控制、现有抗糖尿病药物及其安全性方面的知识状况，以及正在开发的改善这一脆弱人群的肾功能和心血管结局的新疗法。
Zotero 插件